Combination therapy for advanced HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (chidamide, a PD-1 inhibitor, and anlotinib) to see if they can shrink or slow the growth of advanced breast cancer that is HER2-low and hormone receptor positive, and has stopped responding to endocrine therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must have spread to other parts of the body or cannot be removed with surgery.
- Your tumor must be HER2-low, meaning a score of 1+ or 2+ without a positive gene test.
- Your cancer must be hormone receptor positive, meaning it uses hormones to grow.
- You must have tried endocrine therapy and it stopped working.
- You must have had 0 or 1 prior chemotherapy treatments for recurrent or metastatic cancer.
- Your tumor must test positive for PD-L1 (with a CPS score of 1 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a new combination of targeted therapies (inetetamab plus rapamycin) with chemotherapy for HER2-positive breast cancer that has spread or come back and has a specific genetic change (PAM pathway mutation). It aims to see if this combination can work better than current treatments for people whose cancer has progressed after trastuzumab.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.